PDCD1 and esophageal squamous cell carcinoma: Notably, second‐line PD‐1 inhibitor‐based combination therapies showed more clinical benefits as compared with the standard PD‐1 inhibitor monotherapy in immunotherapy‐naive ESCC patients.